Hepatokines: unlocking the multi-organ network in metabolic diseases

Diabetologia

Volumn 58, Issue 8, 2015, Pages 1699-1703

  Iroz, Alison ^a,b   Couty, Jean Pierre ^a,b   Postic, Catherine ^a,b  

^a INSTITUT COCHIN   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Beta cell; Glucose homeostasis; Hepatokines; Liver; Metabolic diseases; NAFLD; Type 2 diabetes

Indexed keywords

ANGIOPOIETIN LIKE PROTEIN 8; BETATROPHIN; FETUIN A; FIBROBLAST GROWTH FACTOR 21; HEPATOKINE; LIVER PROTEIN; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; LIPASIN PROTEIN, HUMAN; PEPTIDE HORMONE;

EDITORIAL; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; ANIMAL; LIVER; METABOLISM; OBESITY;

ALPHA-2-HS-GLYCOPROTEIN; ANIMALS; DIABETES MELLITUS, TYPE 2; FIBROBLAST GROWTH FACTORS; HUMANS; INSULIN RESISTANCE; LIVER; METABOLIC DISEASES; OBESITY; PEPTIDE HORMONES;

EID: 84937522427     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-015-3634-4     Document Type: Editorial

References (23)

1. Stefan N, Haring HU (2013) The role of hepatokines in metabolism. Nat Rev Endocrinol 9:144–152
2. Kharitonenkov A, Adams AC (2014) Inventing new medicines: the FGF21 story. Mol Metab 3:221–229
3. Gimeno RE, Moller DE (2014) FGF21-based pharmacotherapy—potential utility for metabolic disorders. Trends Endocrinol Metab 25:303–311
4. Coleman DL (1973) Effects of parabiosis of obese with diabetes and normal mice. Diabetologia 9:294–298
5. Michael MD, Kulkarni RN, Postic C et al (2000) Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 6:87–97
6. Pal D, Dasgupta S, Kundu R et al (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18:1279–1285
7. Ochi A, Mori K, Emoto M et al (2014) Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. PLoS One 9, e88704
8. Banting FG, Best CH (1922) The internal secretion of the pancreas. J Lab Clin Med 7:251–266
9. El Ouaamari A, Kawamori D, Dirice E et al (2013) Liver-derived systemic factors drive beta cell hyperplasia in insulin-resistant states. Cell Rep 3:401–410
10. Yi P, Park JS, Melton DA (2013) Betatrophin: a hormone that controls pancreatic beta cell proliferation. Cell 153:747–758
11. Gusarova V, Alexa CA, Na E et al (2014) ANGPTL8/betatrophin does not control pancreatic beta cell expansion. Cell 159:691–696
12. Cox AR, Lam CJ, Bonnyman CW, Chavez J, Rios JS, Kushner JA (2015) Angiopoietin-like protein 8 (ANGPTL8)/betatrophin overexpression does not increase beta cell proliferation in mice. Diabetologia. doi:10.1007/s00125-015-3590-z
13. Espes D, Lau J, Carlsson PO (2014) Increased circulating levels of betatrophin in individuals with long-standing type 1 diabetes. Diabetologia 57:50–53
14. Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E (2007) Hepatic fibroblast growth factor 21 is regulated by PPARα and is a key mediator of hepatic lipid metabolism in ketotic states. Cell Metab 5:426–437
15. Iizuka K, Takeda J, Horikawa Y (2009) Glucose induces FGF21 mRNA expression through ChREBP activation in rat hepatocytes. FEBS Lett 583:2882–2886
16. Dushay JR, Toschi E, Mitten EK, Fisher FM, Herman MA, Maratos-Flier E (2014) Fructose ingestion acutely stimulates circulating FGF21 levels in humans. Mol Metab 4:51–57
17. Dushay J, Chui PC, Gopalakrishnan GS et al (2010) Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:456–463
18. Abdul-Wahed A, Gautier-Stein A, Casteras S et al (2014) A link between hepatic glucose production and peripheral energy metabolism via hepatokines. Mol Metab 3:531–543
19. Anson M, Crain-Denoyelle AM, Baud V et al (2012) Oncogenic β-catenin triggers an inflammatory response that determines the aggressiveness of hepatocellular carcinoma in mice. J Clin Invest 122:586–599
20. Okumura A, Unoki-Kubota H, Matsushita Y et al (2013) Increased serum leukocyte cell-derived chemotaxin 2 (LECT2) levels in obesity and fatty liver. Biosci Trends 7:276–283
21. Yu H, Xia F, Lam KS et al (2011) Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem 57:691–700
22. Gaich G, Chien JY, Fu H et al (2013) The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. Cell Metab 18:333–340
23. Kim JH, Bae KH, Choi YK et al (2015) Fibroblast growth factor 21 analogue LY2405319 lowers blood glucose in streptozotocin-induced insulin-deficient diabetic mice by restoring brown adipose tissue function. Diabetes Obes Metab 17:161–169